Australian radiopharmaceutical company
Australian radiopharmaceutical company
Telix Pharmaceuticals agrees to acquire ITM Isotope Technologies Munich for up to $2.35 billion, securing isotope supply and adding ITM-11, a Phase 3 neuroendocrine tumour candidate that received an FDA …
You must be logged in to post a comment.